New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GDOT;ELN;MRK;CTRP;DELL;NFLX;MAT;MCK;VVUS;ALKS;ADNC;LTM;TSN From The Last 14 Days
Check below for free stories on GDOT;ELN;MRK;CTRP;DELL;NFLX;MAT;MCK;VVUS;ALKS;ADNC;LTM;TSN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 16, 2014
17:23 EDTTSNTyson Foods commences tender offer for Hillshire Brands for $63 per share cash
Tyson Foods (TSN) announced that it has commenced a cash tender offer for all outstanding shares of common stock of Hillshire Brands (HSH) at a price of $63.00 per share. The tender offer is being made pursuant to the previously announced merger agreement dated July 1, among the two companies and HMB Holdings, a wholly owned subsidiary of Tyson Foods. The tender offer period will expire at 12:00 midnight at the end of the day on August 12, unless the offer is extended. Tyson Foods has filed a tender offer statement on Schedule TO with the United States SEC. HMB Holdings is the acquirer in the tender offer. The Offer to Purchase contained within the Schedule TO sets out the terms and conditions of the tender offer. Hillshire Brands has also filed a Solicitation/Recommendation Statement with the SEC, which includes the recommendation of the Hillshire board of directors that Hillshire Brands stockholders tender their shares in the tender offer. Following successful completion of the tender offer, any shares not acquired in the tender offer will be acquired in a second-step merger at the same $63 per share cash price.
15:17 EDTNFLXNetflix quietly ends Saturday DVD deliveries to lower costs, LAT says
Subscribe for More Information
14:55 EDTMATMattel July 39 straddle priced for 5.1% move into Q2
Subscribe for More Information
14:03 EDTNFLXNetflix submits FCC comments on proposed Net Neutrality rules
Subscribe for More Information
11:50 EDTMATMattel technical comments before earnings
Subscribe for More Information
09:37 EDTNFLXActive equity options trading on open
Subscribe for More Information
06:26 EDTMRKBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
11:13 EDTMRKPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
08:11 EDTMRKMerck looks to revive livestock drug Zilmax, WSJ says
Merck has been preparing to conduct a large-scale study this summer to evaluate the safety of its Zilmax feed additive, which the company pulled from the U.S. market last year over concerns in the beef industry that the drug made it difficult for some animals to walk, reported The Wall Street Journal. Reference Link
08:03 EDTNFLXPublic speak out on FCC 'net-neutrality' plan, WSJ says
The Federal Communications Commission's has received more than 677K comments so far from the public on its proposed 'net-neutrality' rules for how broadband providers can treat content traveling over their networks and a random sampling of the input suggests that the agency will have work to do to sell the plan, according to The Wall Street Journal. Companies that provide broadband Internet service include Comcast (CMCSA), AT&T (T), Verizon (VZ) Time Warner Cable (TWC), and Cablevision (CVC). Netflix (NFLX) sends a great deal of content over the Internet and strongly supports net neutrality. Reference Link
07:35 EDTMRKPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
July 14, 2014
16:00 EDTNFLXOptions Update; July 14, 2014
Subscribe for More Information
July 12, 2014
12:37 EDTADNCAudience completes acquisition of Sensor Platforms
Audience announced that it has completed its acquisition of Sensor Platforms. Sensor Platforms develops software and algorithms that interpret sensor data to enable broad context awareness on smartphones, wearables and other smart devices. Audience believes the combination of its Advanced Voice and Multisensory Processing with Sensor Platforms' technology places the combined company in a unique position to deliver compelling solutions based on the fusion of voice and motion. The company noted, "Joining these technologies will help transform the way consumers engage with devices, by enabling seamless natural user experiences, always-on sensor fusion, and context-aware services." With the close of the acquisition, the Sensor Platforms' team is now part of Audience. The acquisition was completed on July 11 for consideration of $41M of cash.
July 11, 2014
08:59 EDTNFLXNetflix price target to $500 on international opportunity at Raymond James
Subscribe for More Information
07:38 EDTALKSHouse Energy & Commerce Committee to hold a hearing
Subscribe for More Information
07:25 EDTMATMattel July volatility elevated into Q2 and outlook
Mattel July call option implied volatility is at 40, August is at 23, October is at 20; compared to its 26-week average of 22 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on July 17.
06:10 EDTNFLXJPMorgan expects solid Q2 results in Internet space
Subscribe for More Information
July 10, 2014
16:12 EDTMRKMedivation names Dawn Svoronos as Chief Commercial Officer
Medivation (MDVN) announced Dawn Svoronos has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, CEO and president of Medivation. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. (MRK), where she oversaw commercial operations in approximately 30 EU and EU accession countries. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the company to pursue other opportunities.
16:00 EDTNFLXOptions Update; July 10, 2014
Subscribe for More Information
08:03 EDTMCKAccretive Health names Emad Rizk as CEO and president
Accretive Health (ACHI) announced that its Board of Directors has appointed Emad Rizk, M.D., president of McKesson Health Solutions (MCK), as CEO, President, and a member of the Board of Directors, effective July 21.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use